Government-Owned Inventions; Availability for Licensing, 26070-26071 [2018-12017]

Download as PDF 26070 Federal Register / Vol. 83, No. 108 / Tuesday, June 5, 2018 / Notices this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NCI-Shady Grove campus. All visitors will be asked to show one form of identification (for example, a governmentissued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: NCAB: https:// deainfo.nci.nih.gov/advisory/ncab/ncab.htm, BSA: https://deainfo.nci.nih.gov/advisory/ bsa/bsa.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: May 30, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–11958 Filed 6–4–18; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings amozie on DSK3GDR082PROD with NOTICES1 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Summer Research Education Experience Programs. Date: June 19, 2018. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive 20:19 Jun 04, 2018 Jkt 241001 Dated: May 30, 2018. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–11963 Filed 6–4–18; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES VerDate Sep<11>2014 Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Ernest W. Lyons, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd, Suite 3208, MSC 9529, Bethesda, MD 20892–9529, (301) 496–4056, lyonse@ninds.nih.gov. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Research Education Programs for Residents and Fellows. Date: June 29, 2018. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Ernest W. Lyons, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd, Suite 3208, MSC 9529, Bethesda, MD 20892–9529, (301) 496–4056, lyonse@ninds.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development, Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC 2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve SUMMARY: PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. A description of the technology follows. Octopod (8-Pointed Star) Iron Oxide Nanoparticles Enhance MRI T2 Contrast Description of Technology: The octopod-shaped iron oxide nanoparticles of this technology significantly enhance contrast in MRI imaging compared to spherical superparamagnetic iron oxide nanoparticle T2 contrast agents. These octopod iron oxide nanoparticles show a transverse relaxivity that is over five times greater than comparable spherical agents. Because the unique octopod shape creates a greater effective radius than spherical agents, but maintains similar magnetization properties, the relaxation rate is improved. The improved relaxation rate greatly enhances the contrast of images. These octopod agents appear to be biocompatible and may be suitable for intravenous delivery. The synthesis of these agents is also easily reproducible and scaled. The superior contrast greatly improves diagnostic sensitivities, compared to current FDA approved spherical contrast agents. These octopod-shaped iron oxide nanoparticle T2 contrast agents may have a number of medical imaging uses, such as tumor detection, atherosclerosis imaging and delivery of therapeutic treatments. Potential Commercial Applications: Medical imaging, such as tumor detection, atherosclerosis imaging and delivery of therapeutic treatments. Competitive Advantages: —Enhanced T2 contrast —Reproducible and scalable synthesis —Improved imaging and diagnostic capability Development Stage: In vivo data available (animal). Inventors: Xiaoyuan Chen (NIBIB), Jinhao Gao (Xiamen University, China), Zhenghuan Zhao (Xiamen University, China). Publication: Zhao Z, et al. Octapod iron oxide nanoparticles as highperformance T2 contrast agents for magnetic resonance imaging. Nat Commun. 2013;4:2266. [PMID 23903002] Intellectual Property: HHS Reference No. E–314–2013/0—PCT Application No. PCT/CN2013/076645 filed June 3, 2013. Chinese Patent Application 201380077163.3 filed December 3, 2015. E:\FR\FM\05JNN1.SGM 05JNN1 Federal Register / Vol. 83, No. 108 / Tuesday, June 5, 2018 / Notices European Patent 3003394 issued May 23, 2018 (validated in Switzerland, Germany, France, the United Kingdom, and Ireland), U.S. Patent 9,974,868 issued May 22, 2018. Licensing Contact: Michael A. Shmilovich; 301–435–5019; shmilovm@ mail.nih.gov. Collaborative Research Opportunity: The National Institute of Biomedical Imaging and Bioengineering is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Cecilia Pazman, Ph.D. at pazmance@mail.nih.gov. Dated: May 21, 2018. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2018–12017 Filed 6–4–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review: Notice of Closed Meetings amozie on DSK3GDR082PROD with NOTICES1 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR–18– 669: Limited Competition: Specific Pathogen Free Macaque Colonies. Date: June 28, 2018. Time: 10:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Barna Dey, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, Bethesda, MD 20892, 301–451–2796, bdey@ mail.nih.gov. VerDate Sep<11>2014 20:19 Jun 04, 2018 Jkt 241001 Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA–RM– 18–016: Innovative Technologies to Deliver Genome Editing Machinery to Diseaserelevant Cells and Tissues. Date: June 29, 2018. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Luis Dettin, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2208, Bethesda, MD 20892, 301 451 1327, dettinle@ csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cancer Immunopathology and Immunotherapy. Date: July 3, 2018. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Lawrence Ka-Yun Ng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6152, MSC 7804, Bethesda, MD 20892, 301–435– 1719, ngkl@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: May 30, 2018. David D. Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–11957 Filed 6–4–18; 8:45 am] 26071 would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review of Centers of Biomedical Research Excellence (COBRE) (P20) Applications. Date: July 16, 2018. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Cambria Hotel & Suite Rockville, 1 Helen Heneghan Way, Rockville, MD 20850. Contact Person: Manas Chattopadhyay, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Building 45, Room 3An12N, 45 Center Drive, Bethesda, md 20892, 301–827– 5320, manasc@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS) Dated: May 30, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–11960 Filed 6–4–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of General Medical Sciences; Notice of Closed Meeting BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of General Medical Sciences; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review of NIH Pathway to Independence Award K99/R00 Applications. Date: July 19, 2018. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\05JNN1.SGM 05JNN1

Agencies

[Federal Register Volume 83, Number 108 (Tuesday, June 5, 2018)]
[Notices]
[Pages 26070-26071]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-12017]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development, Office of Technology 
Transfer, 31 Center Drive, Room 4A29, MSC 2479, Bethesda, MD 20892-
2479; telephone: 301-402-5579. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing. A description of the 
technology follows.

Octopod (8-Pointed Star) Iron Oxide Nanoparticles Enhance MRI T2 
Contrast

    Description of Technology: The octopod-shaped iron oxide 
nanoparticles of this technology significantly enhance contrast in MRI 
imaging compared to spherical superparamagnetic iron oxide nanoparticle 
T2 contrast agents. These octopod iron oxide nanoparticles show a 
transverse relaxivity that is over five times greater than comparable 
spherical agents. Because the unique octopod shape creates a greater 
effective radius than spherical agents, but maintains similar 
magnetization properties, the relaxation rate is improved. The improved 
relaxation rate greatly enhances the contrast of images. These octopod 
agents appear to be bio-compatible and may be suitable for intravenous 
delivery. The synthesis of these agents is also easily reproducible and 
scaled. The superior contrast greatly improves diagnostic 
sensitivities, compared to current FDA approved spherical contrast 
agents. These octopod-shaped iron oxide nanoparticle T2 contrast agents 
may have a number of medical imaging uses, such as tumor detection, 
atherosclerosis imaging and delivery of therapeutic treatments.
    Potential Commercial Applications: Medical imaging, such as tumor 
detection, atherosclerosis imaging and delivery of therapeutic 
treatments.
    Competitive Advantages:

--Enhanced T2 contrast
--Reproducible and scalable synthesis
--Improved imaging and diagnostic capability

    Development Stage: In vivo data available (animal).
    Inventors: Xiaoyuan Chen (NIBIB), Jinhao Gao (Xiamen University, 
China), Zhenghuan Zhao (Xiamen University, China).
    Publication: Zhao Z, et al. Octapod iron oxide nanoparticles as 
high-performance T2 contrast agents for magnetic resonance imaging. Nat 
Commun. 2013;4:2266. [PMID 23903002]
    Intellectual Property: HHS Reference No. E-314-2013/0--PCT 
Application No. PCT/CN2013/076645 filed June 3, 2013. Chinese Patent 
Application 201380077163.3 filed December 3, 2015.

[[Page 26071]]

European Patent 3003394 issued May 23, 2018 (validated in Switzerland, 
Germany, France, the United Kingdom, and Ireland), U.S. Patent 
9,974,868 issued May 22, 2018.
    Licensing Contact: Michael A. Shmilovich; 301-435-5019; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Biomedical Imaging and Bioengineering is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize this technology. 
For collaboration opportunities, please contact Cecilia Pazman, Ph.D. 
at [email protected].

    Dated: May 21, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-12017 Filed 6-4-18; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.